TY - JOUR
T1 - Urological cancer risk in patients with rheumatoid arthritis compared to matched controls
T2 - a nationwide cohort study
AU - Lee, Dagyeong
AU - Jeon, Keun Hye
AU - Jung, Jinhyung
AU - Han, Kyungdo
AU - Cho, Mi Hee
AU - Cho, In Young
AU - Shin, Dong Wook
N1 - Publisher Copyright:
© The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.
PY - 2025/6/1
Y1 - 2025/6/1
N2 - Objective: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with several comorbidities, including an increased risk of certain cancers. This study aimed to investigate the potential associations between RA and increased risk of urological cancers – specifically kidney, bladder, prostate and testicular cancers – and the influence of RA serological status on this risk. Methods: This retrospective cohort study used data from the Korean National Health Insurance System database (2010–2020), including patients with RA and a 1:5 matched non-RA population. RA patients were grouped according to serological status. The primary outcome was newly diagnosed urological cancer, and its association with RA was analysed by Cox proportional hazards regression analyses adjusting for potential confounders. Results: RA patients had an increased risk of kidney cancer compared with the non-RA population fadjusted hazard ratio (aHR), 1.34 [95% confidence interval (CI), 1.04–1.78]g. The risk of kidney cancer was even higher in women with RA [aHR 1.57 (95% CI: 1.10, 2.24)]. However, the risk of bladder, prostate and testicular cancers was not associated with RA (bladder cancer, aHR 1.24, 95% CI 0.95–1.62; prostate cancer, aHR 1.13, 95% CI 0.94–1.35; testicular cancer, aHR 2.31, 95% CI 0.44–12.20). No significant difference in urological cancer risk was found according to serological status. Conclusions: RA patients have a higher risk of kidney cancer than the general population. Further research is needed to understand the mechanisms underlying the association between RA and kidney cancer to optimize cancer prevention and screening strategies.
AB - Objective: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with several comorbidities, including an increased risk of certain cancers. This study aimed to investigate the potential associations between RA and increased risk of urological cancers – specifically kidney, bladder, prostate and testicular cancers – and the influence of RA serological status on this risk. Methods: This retrospective cohort study used data from the Korean National Health Insurance System database (2010–2020), including patients with RA and a 1:5 matched non-RA population. RA patients were grouped according to serological status. The primary outcome was newly diagnosed urological cancer, and its association with RA was analysed by Cox proportional hazards regression analyses adjusting for potential confounders. Results: RA patients had an increased risk of kidney cancer compared with the non-RA population fadjusted hazard ratio (aHR), 1.34 [95% confidence interval (CI), 1.04–1.78]g. The risk of kidney cancer was even higher in women with RA [aHR 1.57 (95% CI: 1.10, 2.24)]. However, the risk of bladder, prostate and testicular cancers was not associated with RA (bladder cancer, aHR 1.24, 95% CI 0.95–1.62; prostate cancer, aHR 1.13, 95% CI 0.94–1.35; testicular cancer, aHR 2.31, 95% CI 0.44–12.20). No significant difference in urological cancer risk was found according to serological status. Conclusions: RA patients have a higher risk of kidney cancer than the general population. Further research is needed to understand the mechanisms underlying the association between RA and kidney cancer to optimize cancer prevention and screening strategies.
KW - bladder cancer
KW - kidney cancer
KW - prostate cancer
KW - rheumatoid arthritis
KW - testicular cancer
UR - https://www.scopus.com/pages/publications/105006688549
U2 - 10.1093/rheumatology/keaf103
DO - 10.1093/rheumatology/keaf103
M3 - Article
C2 - 39951303
AN - SCOPUS:105006688549
SN - 1462-0324
VL - 64
SP - 3458
EP - 3467
JO - Rheumatology (United Kingdom)
JF - Rheumatology (United Kingdom)
IS - 6
ER -